Effect of crocin on depression induced by amphetamine withdrawal

Assessment of additive effects of crocin in men with depression induced by amphetamine withdrawal

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160804029191N3

Enrollment

Registered

2021-12-02

Start date

2022-01-21

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression. Recurrent depressive disorder

Interventions

Intervention 1: Control group: In this group, patients (n=30) will receive placebo tablet (Containing Avicel, made by School of Pharmacy, Mashhad University of Medical Sciences), daily for 12 weeks. I

Eligibility

Sex/Gender

Male

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Men with moderate depression induced by amphetamine withdrawal Being 20-50 years old Patient consent to participate in the study Not having specific physical (e.g. cancer, Acquired immunodeficiency syndrome (AIDS), Multiple Sclerosis (MS)) or mental illness Not having allergic to saffron/crocin

Exclusion criteria

Exclusion criteria: Lack of patient cooperation in Crocin consumption Having allergic reaction or intolerable side effect caused by crocin

Design outcomes

Primary

Measure	Time frame
Beck Depression Inventory (BDI) questionnaire. Timepoint: Before treatment (day 0) and at the end of weeks 4, 8 and 12 after starting treatment. Method of measurement: Completion of the questionnaire by patient or researcher.;General Health Questionnaire (GHQ). Timepoint: Before treatment (day 0) and at the end of weeks 4, 8 and 12 after starting treatment. Method of measurement: Completion of the questionnaire by patient or researcher.	—

Measure

Time frame

Beck Depression Inventory (BDI) questionnaire. Timepoint: Before treatment (day 0) and at the end of weeks 4, 8 and 12 after starting treatment. Method of measurement: Completion of the questionnaire by patient or researcher.;General Health Questionnaire (GHQ). Timepoint: Before treatment (day 0) and at the end of weeks 4, 8 and 12 after starting treatment. Method of measurement: Completion of the questionnaire by patient or researcher.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRamin Rezaee

Mashhad University of Medical Sciences

RezaeeRA@mums.ac.ir+98 51 3802 2089

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026